Healthcare Sector News
Last published 14m ago
- 14m agoKODKodiak Sciences to Present at Three Upcoming Investor ConferencesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and...
- 1h agoMLSSCORRECTION: Milestone Scientific Schedules Third Quarter 2026 Financial Results Conference CallGlobeNewswireIn a release issued under the same headline earlier today by Milestone Scientific, Inc., please note that in the first paragraph of the release, the conference call date should have been Friday, November 13, not Wednesday, November 13, as previously stated .
- 1h agoNVAXNovavax to Participate in Jefferies London Healthcare ConferencePR NewswireNovavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies...
- 2h agoGILDFeds arrest top official of healthcare company, alleging illegal drug importationCNBCU.S. officials are accusing two top officials of a Canadian company of operating a scheme to illegally import prescription drugs, court records show.
- 2h agoADXNAddex Spin-out Neurosterix Closes $105 Million Series B FinancingGlobeNewswireAd Hoc Announcement Pursuant to Art. 53 LR
- 2h agoCSTLCastle Biosciences to Present at the Piper Sandler 38th Annual Healthcare ConferencePR NewswireCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
- 2h agoCAHCardinal Health Board of Directors Approves Quarterly DividendPR NewswireCardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5158 per share, out of the...
- 2h agoPFEPfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity ProgramBusiness WireNEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs through 2028 for berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chro ...
- 2h agoGHGuardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032Business WirePALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A u ...
- 2h agoMLSSMilestone Scientific Schedules Third Quarter 2026 Financial Results Conference CallGlobeNewswireROSELAND, N.J., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments...
- 2h agoALVOAlvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business UpdateGlobeNewswireREYKJAVIK, ICELAND (November 11, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in...
- 2h agoALVOAlvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business UpdateGlobeNewswireREYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company...
- 2h agoNKTRNektar Therapeutics to Participate in Two Investor Conferences in NovemberPR NewswireNektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences. UBS...
- 2h agoSGPSpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireIRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.
- 2h agoICUSeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireContinued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025
- 2h agoNSPRInspireMD Announces Updated Timing for Third Quarter 2026 Financial ResultsGlobeNewswireMIAMI, Nov. 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it has rescheduled its third quarter 2026 financial results conference call and webcast to 4:30 p.m. Eastern Time, after the close of U.S. financial markets on Thursday, November 12, 2026, from its previously announced time ...
- 2h agoIRTCiRhythm Announces Approval of $200 Million Share Repurchase ProgramGlobeNewswireSAN FRANCISCO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that on November 10, 2026, its Board of Directors approved a share repurchase program with authorization to purchase up to $200 million of the company’s outstanding common ...
- 2h agoACOGAlpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational UpdateBusiness WireVANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “The third quart ...
- 2h agoONCYOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal CarcinomaGlobeNewswireOncolytics Biotech® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI® (toripalimab-tpzi) in Squamous Cell Anal Carci
- 2h agoAIRSAirSculpt Technologies Announces First-Ever Nationwide Open House Event, "The Gift of Body Confidence"GlobeNewswireEvent to Offer Prospective and Existing Patients Access to AirSculpt Surgeons, Personalized Consultations and Educational Programming Across 31 Centers and Virtually
- 2h agoVANIVivani Medical Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTop-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week
- 2h agoXAIRBeyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026GlobeNewswireRecord quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH
- 2h agoWGSGeneDx to Participate in Upcoming Investor ConferencesBusiness WireGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences
- 2h agoATECATEC Announces Participation in Upcoming Investor ConferencesBusiness WireCARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conference(s): Management will host one-on-one investor meetings and participate in a fireside chat at Piper Sandler’s 38th Annual Healthcare Conference he ...
- 2h agoENGNenGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBCBusiness WireBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene). Data from Cohort 1, which enrolled 125 patients with high-risk, Bacillus Calmette-Guérin ...
- 2h agoENGNenGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial MilestonesBusiness WireBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026. enGene's lead investigational candidate, detalimogene voraplasmid ...
- 2h agoDCTHDelcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer TreatmentBusiness WireQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer.” The segment is scheduled to air nationally on Sunday ...
- 2h agoLKFTLakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business UpdateGlobeNewswireGamgertamig poster accepted for presentation at the 2026 ASH 1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”
- 2h agoKNSAKiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswireLONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time).
- 2h agoOPRXOptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 GuidanceGlobeNewswireQ3 revenue totals $21.6 millionQ3 net income and adjusted EBITDA of $1.2 million and $6.3 million2026 revenue guidance updated to $87-$93 million; adjusted...
- 3h agoGMABTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsGlobeNewswireCompany Announcement
- 5h agoMDGLKaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law ViolationsGlobeNewswireKaplan Fox is investigating potential securities law violations by Madrigal Pharmaceuticals (NASDAQ: MDGL) after its stock fell on Nov. 3, 2026....
- 5h agoLLYHIMSNVDANasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek RallyPR NewswireStock Preachers News Commentary - Stocks staged a broad midweek advance, with the Nasdaq Composite climbing 2.06% on the session and 4.08% for...
- 7h agoNTHIINLFCRWVOMHBrain Cancer Breakthrough Hopes, a $30 Million Robotics Deal and an AI Gold RushGlobeNewswire$NTHI, $INLF, $CRWV, and $OMH are among today’s best stocks in the news
- 7h agoMRNAModerna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and OlderACCESS NewswireModerna, Inc. (NASDAQ:MRNA) today announced the publication of results from a large real-world study evaluating the comparative effectiveness of mNEXSPIKE® (COVID-19 Vaccine, mRNA) and Comirnaty® (COVID-19 Vaccine, mRNA) among U.S. Veterans aged 65 years and older during the 2025-2026 respiratory virus season. The analysis, published in JAMA Network Open, included 294,499 matched participants in t ...
- 9h agoLLYNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesityPR NewswireNearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to...
- 9h agoBMGLTrading halt: Basel Medical Group Ltd Ord Sh (BMGL), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-11 09:40:49.276 ET, resumption quote 2026-11-11 09:40:49 ET, resumption trade none.
- 9h agoMTRITrading halt: Mentari Therapeutics, Inc. Cmn (MTRI), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-11 09:32:33.436 ET, resumption quote 2026-11-11 09:32:33 ET, resumption trade none.
- 9h agoBMGLTrading halt: Basel Medical Group Ltd Ord Sh (BMGL), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-11 09:31:03.876 ET, resumption quote 2026-11-11 09:31:03 ET, resumption trade none.
- 9h agoCOSMCosmos Health Provides U.S. E-Commerce Update for October 2026: Monthly Subscription Value Reaches $1.83 Million, Approximately $22 Million AnnualizedACCESS NewswireCosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its U.S. direct-to-consumer subscription business reached $1,832,785 in monthly subscription value as of October 31, 2026, equivalent to approximately $22.0 million on an annualized basis. In October 2026, the Company's U.S. e-commerce business rec ...
- 9h agoSINTSINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant CommercializationGlobeNewswireCompany completes additive manufacturing facility buildout, advances proprietary silicon nitride–PEEK technology, expands leadership and targets initial product availability in 2027
- 9h agoNXGLNXGLWNEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital FundingGlobeNewswireApproximately 95% of Outstanding Convertible Note Principal Committed to Conversion, Subject to Completion of a Strategic Merger
- 9h agoCVSCVS Health earns global recognition for industry-leading AI and technology innovationPR NewswireCVS Health® (NYSE: CVS) is being recognized with seven Stevie® Awards for technology and responsible AI innovations that are simplifying access...
- 9h agoPMCBPharmaCyte Biotech, Inc. Announces Reverse Stock SplitBusiness WireLAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that the board of directors of the Company approved a 1-for-19 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders at the Company’s annual meeting of the stockholders held on March 30, 2026. The Reverse Split wil ...
- 9h agoAPVOAptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross ProceedsACCESS NewswireAptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full fo ...
- 9h agoTDOCAMWLDOCSHIMSA $400 Billion Healthcare Opportunity: Telehealth Companies Positioned to Capitalize on a Massive Industry ShiftGlobeNewswireHealthcare Innovation and Technology Adoption Are Reshaping How Millions of Patients Access Medical Services
- 9h agoVNDANEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art WeekPR NewswireVanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that "NEREUS™ – The Goat of Biscayne Bay" is arriving during Miami Art Week, offering...
- 10h agoTPSTTempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D CandidateGlobeNewswire-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates
- 10h agoGHGuardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® LiquidBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists understand how a patient’s cancer may respond to treatment in the absence of traditional biomarkers. The expanded capabilities include five key advances: Two novel epigenomic predictors identify patients ...
- 10h agoAKTXAkari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-HoGlobeNewswireDiscussion highlights Vat-Ho’s oncology business development experience, his decision to join Akari and the potential of the Company’s novel PH1 payload platform